CTLA-4 blockade with ipilimumab: Biology, safety, efficacy, and future considerations

Cancer Medicine

Volumn 4, Issue 5, 2015, Pages 661-672

  Camacho, Luis H ^a  

^a St Luke's Belmont Center   (United States)

Author keywords

CTLA 4; CTLA4; Immunotherapy; Ipilimumab; Melanoma; Survival

Indexed keywords

CORTICOSTEROID; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG SAFETY; HUMAN; METASTATIC MELANOMA; NAUSEA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SKIN PRURITUS; TREATMENT RESPONSE; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; DISEASE MANAGEMENT; MELANOMA; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MELANOMA; TREATMENT OUTCOME;

EID: 85006217674     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.371     Document Type: Article

References (59)

1. Siegel, R., J. Ma, Z. Zou, and A. Jemal . 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64:9-29.
2. Jemal, A., S. S. Devesa, P. Hartge, and M. A. Tucker . 2001. Recent trends in cutaneous melanoma incidence among whites in the United States. J. Natl Cancer Inst. 93:678-683.
3. Korn, E. L., P. Y. Liu, S. J. Lee, J. A. Chapman, D. Niedzwiecki, V. J. Suman, et al. 2008. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26:527-534.
4. Davies, H., G. R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-954.
5. Chapman, P. B., A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507-2516.
6. Hauschild, A., J. J. Grob, L. V. Demidov, T. Jouary, R. Gutzmer, M. Millward, et al. 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365.
7. Flaherty, K. T., C. Robert, P. Hersey, P. Nathan, C. Garbe, M. Milhem, et al. 2012. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367:107-114.
8. Flaherty, K. T., J. R. Infante, A. Daud, R. Gonzalez, R. F. Kefford, J. Sosman, et al. 2012. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367:1694-1703.
9. Cheng, S., P. Chu, M. Hinshaw, K. Smith, J. Maize, and A. Sferruzza . 2011. Frequency of mutations associated with targeted therapy in malignant melanoma patients. J. Clin. Oncol. 29(Suppl.):abstr 8597.
10. Brunet, J. F., F. Denizot, M. F. Luciani, M. Roux-Dosseto, M. Suzan, M. G. Mattei, et al. 1987. A new member of the immunoglobulin superfamily-CTLA-4. Nature 328:267-270.
11. Brunet, J. F., F. Denizot, and P. Golstein . 1988. A differential molecular biology search for genes preferentially expressed in functional T lymphocytes: the CTLA genes. Immunol. Rev. 103:21-36.
12. Krummel, M. F., and J. P. Allison . 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459-465.
13. Ribas, A., L. H. Camacho, G. Lopez-Berestein, D. Pavlov, C. A. Bulanhagui, R. Millham, et al. 2005. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J. Clin. Oncol. 23:8968-8977.
14. Camacho, L. H., S. Antonia, J. Sosman, J. M. Kirkwood, T. F. Gajewski, B. Redman, et al. 2009. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27:1075-1081.
15. Ribas, A., R. Kefford, M. A. Marshall, C. J. Punt, J. B. Haanen, M. Marmol, et al. 2013. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31:616-622.
16. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-723.
17. Melero, I., S. Hervas-Stubbs, M. Glennie, D. M. Pardoll, and L. Chen . 2007. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7:95-106.
18. Hoos, A., R. Ibrahim, A. Korman, K. Abdallah, D. Berman, V. Shahabi, et al. 2010. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 37:533-546.
19. Weber, J. 2010. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol. 37:430-439.
20. Boasberg, P., O. Hamid, and S. O'Day . 2010. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin. Oncol. 37:440-449.
21. Camacho, L. H. 2008. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675, 206), a fully human monoclonal antibody. Expert Opin. Investig. Drugs 17:371-385.
22. Young, S. E., A. E. Giuliano, and D. L. Morton . 2005. Three decades of evolving treatment for melanoma: no improvement in survival? J. Clin. Oncol. 23(Suppl.):abstr 7511.
23. Robert, C., L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, et al. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364:2517-2526.
24. O'Day, S. J., M. Maio, V. Chiarion-Sileni, T. F. Gajewski, H. Pehamberger, I. N. Bondarenko, et al. 2010. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21:1712-1717.
25. Wolchok, J. D., J. S. Weber, M. Maio, B. Neyns, K. Harmankaya, K. Chin, et al. 2013. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann. Oncol. 24:2174-2180.
26. Wolchok, J. D., B. Neyns, G. Linette, S. Negrier, J. Lutzky, L. Thomas, et al. 2010. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11:155-164.
27. Weber, J., J. A. Thompson, O. Hamid, D. Minor, A. Amin, I. Ron, et al. 2009. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15:5591-5598.
28. Schadendorf, D., F. S. Hodi, C. Robert, J. S. Weber, K. Margolin, and O. Hamid, et al. 2013. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur. J. Cancer 49(Suppl. 3):abstr LBA24.
29. Wolchok, J. D., A. Hoos, S. O'Day, J. S. Weber, O. Hamid, C. Lebbé, et al. 2009. Guidelines for the evaluation of immune therapy in solid tumors: immune-related response criteria. Clin. Cancer Res. 15:7412-7420.
30. Ibrahim, R., D. Berman, de Pril V., R. W. Humphrey, T. Chen, and M. Messina, et al. 2011. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J. Clin. Oncol. 29(Suppl.):abstr 8583.
31. Dummer R ., M. Maio., O. Hamid, S. J. O'Day, J. Richards, and J. D. Wolchok, et al. 2010. Time to onset and resolution of immune-related adverse events associated with ipilimumab therapy in patients with advanced melanoma. Presented at the Perspectives in Melanoma XIV; 17-18 September 2010; Amsterdam, The Netherlands. Abstract P-0004.
32. Ipilimumab US prescribing information: risk evaluation and mitigation strategy. Available at http://www.yervoy.com/hcp/rems.aspx (accessed on 12 September 2011).
33. Shaw, S. A., L. H. Camacho, I. E. McCutcheon, and S. G. Waguespack . 2007. Transient hypophysitis after cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade. J. Clin. Endocrinol. Metab. 92:1201-1202.
34. Squibb, B.-M. 2011. YERVOY (ipilimumab) [prescribing information]. Bristol-Myers Squibb, Princeton, NJ.
35. Cancer Therapy Evaluation Program (CTEP). Common terminology criteria for adverse events, Version 3.0, DCTD, NCI, NIH, DHHS. Available at http://ctep.cancer.gov (accessed 12 September 2011).
36. Postow, M. A., M. K. Callahan, C. A. Barker, Y. Yamada, J. Yuan, S. Kitano, et al. 2012. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366:925-931.
37. ClinicalTrials.gov. 2012. Phase 3 trial in subjects with metastatic melanoma comparing 3 mg/kg ipilimumab versus 10 mg/kg ipilimumab. Available at http://www.clinicaltrials.gov/ct2/show/NCT01515189 (accessed 12 March 2014).
38. Maker, A. V., J. C. Yang, R. M. Sherry, S. L. Topalian, U. S. Kammula, R. E. Royal, et al. 2006. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 29:455-463.
39. Robert, C., D. Schadendorf, M. Messina, F. S. Hodi, S. O'Day, and MDX investigators. 2013. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin. Cancer Res. 19:2232-2239.
40. National Comprehensive Cancer Network. Melanoma. Vol. 3.2014. Available at http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf (accessed 10 December 2013).
41. Ribas, A., B. Comin-Anduix, B. Chmielowski, J. Jalil, P. de la Rocha, T. A. McCannel, et al. 2009. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin. Cancer Res. 15:6267-6276.
42. Ribas, A., F. S. Hodi, M. Callahan, C. Konto, and J. Wolchok . 2013. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368:1365-1366.
43. Mathew, M., M. Tam, P. A. Ott, A. C. Pavlick, S. C. Rush, B. R. Donahue, et al. 2013. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 23:191-195.
44. Knisely, J. P., J. B. Yu, J. Flanigan, M. Sznol, H. M. Kluger, and V. L. Chiang . 2012. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurg. 117:227-233.
45. Silk, A. W., M. F. Bassetti, B. T. West, C. I. Tsien, and C. D. Lao . 2013. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2:899-906.
46. Barker, C. A., M. A. Postow, S. A. Khan, K. Beal, P. K. Parhar, Y. Yamada, et al. 2013. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol. Res. 1:92-98.
47. Margolin, K., M. S. Ernstoff, O. Hamid, D. Lawrence, D. McDermott, I. Puzanov, et al. 2012. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13:459-465.
48. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793-800.
49. Curiel, T. J., S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562-567.
50. Thompson, R. H., S. M. Kuntz, B. C. Leibovich, H. Dong, C. M. Lohse, W. S. Webster, et al. 2006. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66:3381-3385.
51. Brahmer, J. R., C. G. Drake, I. Wollner, J. D. Powderly, J. Picus, W. H. Sharfman, et al. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28:3167-3175.
52. Hirano, F., K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65:1089-1096.
53. Jin, H. T., R. Ahmed, and T. Okazaki . 2011. Role of PD-1 in regulating T-cell immunity. Curr. Top. Microbiol. Immunol. 350:17-37.
54. Ganghadar, T. C., and R. H. Vonderheide . 2014. Mitigating the toxic effects of anticancer immunotherapy. Nat. Rev. Clin. Oncol. 11:91-99.
55. Topalian, S. L., M. Sznol, D. F. McDermott, H. M. Kluger, R. D. Carvajal, W. H. Sharfman, et al. 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32:1020-1030.
56. Hamid, O., C. Robert, A. Daud, F. S. Hodi, W. J. Hwu, R. Kefford, et al. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:134-144.
57. Robert, C., A. Ribas, J. D. Wolchok, F. S. Hodi, O. Hamid, R. Kefford, et al. 2014. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109-1117.
58. Ribas, A., F. S. Hodi, R. Kefford, O. Hamid, A. Daud, and J. D. Wolchok, et al. 2014. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J. Clin. Oncol. 32(Suppl. 5):abstr LBA9000.
59. Wolchok, J. D., H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, et al. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369:122-133.